Cancer Cell Resistance Against the Clinically Investigated Thiosemicarbazone COTI-2 Is Based on Formation of Intracellular Copper Complex Glutathione Adducts and ABCC1-Mediated Efflux

[Image: see text] COTI-2 is a novel anticancer thiosemicarbazone in phase I clinical trial. However, the effects of metal complexation (a main characteristic of thiosemicarbazones) and acquired resistance mechanisms are widely unknown. Therefore, in this study, the copper and iron complexes of COTI-...

Descripción completa

Detalles Bibliográficos
Autores principales: Bormio Nunes, Julia H., Hager, Sonja, Mathuber, Marlene, Pósa, Vivien, Roller, Alexander, Enyedy, Éva A., Stefanelli, Alessia, Berger, Walter, Keppler, Bernhard K., Heffeter, Petra, Kowol, Christian R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2020
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7706001/
https://www.ncbi.nlm.nih.gov/pubmed/33190481
http://dx.doi.org/10.1021/acs.jmedchem.0c01277

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7706001/
https://www.ncbi.nlm.nih.gov/pubmed/33190481
http://dx.doi.org/10.1021/acs.jmedchem.0c01277

Ejemplares similares